538 related articles for article (PubMed ID: 26503877)
21. PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma.
Richardson PG; Schlossman RL; Alsina M; Weber DM; Coutre SE; Gasparetto C; Mukhopadhyay S; Ondovik MS; Khan M; Paley CS; Lonial S
Blood; 2013 Oct; 122(14):2331-7. PubMed ID: 23950178
[TBL] [Abstract][Full Text] [Related]
22. The blueberry component pterostilbene has potent anti-myeloma activity in bortezomib-resistant cells.
Chen G; Xu Z; Chang G; Hou J; Hu L; Zhang Y; Yu D; Li B; Chang S; Xie Y; Zhang Y; Wei R; Wu H; Xiao W; Sun X; Tao Y; Gao L; Dai B; Shi J; Zhu W
Oncol Rep; 2017 Jul; 38(1):488-496. PubMed ID: 28560392
[TBL] [Abstract][Full Text] [Related]
23. New insights into the treatment of multiple myeloma with histone deacetylase inhibitors.
Cea M; Cagnetta A; Gobbi M; Patrone F; Richardson PG; Hideshima T; Anderson KC
Curr Pharm Des; 2013; 19(4):734-44. PubMed ID: 23016853
[TBL] [Abstract][Full Text] [Related]
24. Incidence and management of adverse events associated with panobinostat in the treatment of relapsed/refractory multiple myeloma.
Moore DC; Arnall JR; Harvey RD
J Oncol Pharm Pract; 2019 Apr; 25(3):613-622. PubMed ID: 30060709
[TBL] [Abstract][Full Text] [Related]
25. EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma.
Tzogani K; van Hennik P; Walsh I; De Graeff P; Folin A; Sjöberg J; Salmonson T; Bergh J; Laane E; Ludwig H; Gisselbrecht C; Pignatti F
Oncologist; 2018 May; 23(5):631-636. PubMed ID: 29192015
[TBL] [Abstract][Full Text] [Related]
26. A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma.
Berenson JR; Hilger JD; Yellin O; Boccia RV; Matous J; Dressler K; Ghazal HH; Jamshed S; Kingsley EC; Harb WA; Noga SJ; Nassir Y; Swift RA; Vescio R
Ann Hematol; 2014 Jan; 93(1):89-98. PubMed ID: 24135804
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and Safety of Panobinostat in Relapsed or/and Refractory Multiple Myeloma: Meta Analyses of Clinical Trials and Systematic Review.
Liu JD; Sun CY; Tang L; Wu YY; Wang QY; Hu B; Hu Y
Sci Rep; 2016 Jun; 6():27361. PubMed ID: 27270478
[TBL] [Abstract][Full Text] [Related]
28. Histone deacetylase inhibitor panobinostat induces calcineurin degradation in multiple myeloma.
Imai Y; Ohta E; Takeda S; Sunamura S; Ishibashi M; Tamura H; Wang YH; Deguchi A; Tanaka J; Maru Y; Motoji T
JCI Insight; 2016 Apr; 1(5):e85061. PubMed ID: 27699258
[TBL] [Abstract][Full Text] [Related]
29. [Histone deacetylase inhibitors: new synergistic third-line option in multiple myeloma].
Stegmann DA
Med Monatsschr Pharm; 2016 Apr; 39(4):142-7. PubMed ID: 27209894
[TBL] [Abstract][Full Text] [Related]
30. Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma.
Offidani M; Polloni C; Cavallo F; Liberati AM; Ballanti S; Pulini S; Catarini M; Alesiani F; Corvatta L; Gentili S; Caraffa P; Boccadoro M; Leoni P; Palumbo A
Leuk Lymphoma; 2012 Sep; 53(9):1722-7. PubMed ID: 22335534
[TBL] [Abstract][Full Text] [Related]
31. Panobinostat for the treatment of acute myelogenous leukemia.
Morabito F; Voso MT; Hohaus S; Gentile M; Vigna E; Recchia AG; Iovino L; Benedetti E; Lo-Coco F; Galimberti S
Expert Opin Investig Drugs; 2016 Sep; 25(9):1117-31. PubMed ID: 27485472
[TBL] [Abstract][Full Text] [Related]
32. Estimating the Economic Impact of Adding Panobinostat to a U.S. Formulary for Relapsed and/or Refractory Multiple Myeloma: A Budget Impact and Cost-Benefit Model.
Bloudek L; Roy A; Kish JK; Siegel DS; Jagannath S; Globe D; Orloski L; Kuriakose ET
J Manag Care Spec Pharm; 2016 Aug; 22(8):991-1002. PubMed ID: 27459662
[TBL] [Abstract][Full Text] [Related]
33. Panobinostat in combination with bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, multicentre phase 2 trial.
Tan D; Phipps C; Hwang WY; Tan SY; Yeap CH; Chan YH; Tay K; Lim ST; Lee YS; Kumar SG; Ng SC; Fadilah S; Kim WS; Goh YT;
Lancet Haematol; 2015 Aug; 2(8):e326-33. PubMed ID: 26688485
[TBL] [Abstract][Full Text] [Related]
34. Panobinostat in lymphoid and myeloid malignancies.
Khot A; Dickinson M; Prince HM
Expert Opin Investig Drugs; 2013 Sep; 22(9):1211-23. PubMed ID: 23826641
[TBL] [Abstract][Full Text] [Related]
35. Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma.
Berdeja JG; Hart LL; Mace JR; Arrowsmith ER; Essell JH; Owera RS; Hainsworth JD; Flinn IW
Haematologica; 2015 May; 100(5):670-6. PubMed ID: 25710456
[TBL] [Abstract][Full Text] [Related]
36. Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment.
Richardson PG; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Guenther A; Nakorn TN; Siritanaratkul N; Schlossman RL; Hou J; Moreau P; Lonial S; Lee JH; Einsele H; Sopala M; Bengoudifa BR; Corrado C; Binlich F; San-Miguel JF
Blood; 2016 Feb; 127(6):713-21. PubMed ID: 26631116
[TBL] [Abstract][Full Text] [Related]
37. Outcomes with panobinostat in heavily pretreated multiple myeloma patients.
Pan D; Mouhieddine TH; Upadhyay R; Casasanta N; Lee A; Zubizarreta N; Moshier E; Richter J
Semin Oncol; 2023; 50(1-2):40-48. PubMed ID: 37005144
[TBL] [Abstract][Full Text] [Related]
38. Panobinostat (Farydak) for multiple myeloma.
Med Lett Drugs Ther; 2015 Aug; 57(1475):e118-9. PubMed ID: 26262884
[No Abstract] [Full Text] [Related]
39. Panobinostat: a review of trial results and future prospects in multiple myeloma.
Libby EN; Becker PS; Burwick N; Green DJ; Holmberg L; Bensinger WI
Expert Rev Hematol; 2015 Feb; 8(1):9-18. PubMed ID: 25410127
[TBL] [Abstract][Full Text] [Related]
40. Panobinostat approved for multiple myeloma.
Cancer Discov; 2015 May; 5(5):OF4. PubMed ID: 25802326
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
